Fig. 2

LAMP5-AS1 knockdown impairs the progression and infiltration of MLL leukemia in vivo. a H&E staining in bone marrow, spleen, and liver sections from mice engrafted with LAMP5-AS1 knockdown MOLM13 cells compared with that in control mice. Mice treated with PBS were the negative controls. GFP+ cells in the tissues are indicated by black arrows. A representative image from three independent mice is shown. Scale bars, 50 μm. b Representative flow cytometry graphs showing the decreased levels of blasts in organ samples from mice treated with LAMP5-AS1 knockdown MOLM13 cells relative to the levels in control mice. Mice treated with PBS were used as the negative controls. c Histogram plots show the statistical values for b. Error bars reflect ± SEM (*p < 0.05, **p < 0.01). d, e Representative flow cytometry graphs showing the CD11b (d) and CD14 (e) markers in the bone marrow from mice treated with LAMP5-AS1 knockdown MOLM13 cells relative to the levels in control mice. The values analyzed by error bars reflect ± SEM (*p < 0.05, **p < 0.01). f Wright-Giemsa staining of bone marrow smears from mice engrafted with human MOLM13 cells transfected with sh-NC or sh-LAMP5-AS1. The staining was enlarged under a × 40 objective lens. Scale bars, 20 μm. g Kaplan-Meier survival curves showing the survival of mice implanted with sh-NC- or sh-LAMP5-AS1-transfected MOLM13 cells. p values were calculated using a log-rank (Mantel-Cox) test (*p < 0.05). h Limiting dilution assays using LAMP5-AS1 knockdown and control MOLM13 cells. The estimated the frequency of leukemia cells with self-renewal capacity is shown on the plot. Mice developed leukemia within 4 weeks post injection, and a recipient mouse was considered positive if GFP+ cells constituted more than 1.0% of all nucleated cells in the blood